Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
Akari Therapeutics Plc - American Depositary Shares (AKTX)
US:NASDAQ Investor Relations:
investor.akaritx.com/investor-relations
Company Research
Source: GlobeNewswire
Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the publication of a new CEO Corner segment, now available on the Company’s website. For this segment, Abizer Gaslightwala, CEO of Akari, provides a corporate update highlighting the Company’s recent progress and key growth opportunities and timelines, what it means for the Company’s path forward. Utilizing its innovative ADC payload platform, Akari is advancing a new class of immuno-oncology ADCs built on the platform of a novel PH1 payload. This payload is designed specifically to target and disrupt the action of the spliceosome and has a unique preclinical efficacy and safety profile with the potential to address an unmet need for oncology patients as a monotherapy or used in combination with checkpoint inhibitors. Akari’s lead candidate,
Show less
Read more
Impact Snapshot
Event Time:
AKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKTX alerts
High impacting Akari Therapeutics Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AKTX
News
- Akari Therapeutics Announces Release of the Next CEO Corner SegmentGlobeNewswire
- Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial OfficerGlobeNewswire
- Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint InhibitorsGlobeNewswire
- Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now AvailableGlobeNewswire
- Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACPGlobeNewswire